{
  "id": 19375448,
  "title": "Vaxcyte at guggenheim healthcare conference: strong vaccine data, long road",
  "url": "https://urgent.news/2026/11/10/vaxcyte-at-guggenheim-healthcare-conference-strong-vaccine-data-long",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-11-10T18:37:38.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/transcripts/vaxcyte-at-guggenheim-healthcare-conference-strong-vaccine-data-long-road-93CH-5016526"
  },
  "original_language": "en",
  "account": "On 10 November 2026, Vaxcyte presented a positive update on its vaccine pipeline at the 3rd Annual Guggenheim Healthcare Innovation Conference. The company's 31-valent pneumococcal conjugate vaccine, VAX-31, showcased strong Phase III results across serotypes, achieving 11-for-11 in primary endpoints compared to existing vaccines PCV20 and PCV21. Vaxcyte aims to submit a Biologics License Application for VAX-31 in the first half of 2028, pending further clinical trials, regulatory, and manufacturing work. The company's cash balance stands at approximately $3.4 billion, fully funding the anticipated adult launch, with shares trading at $66.72, giving the company a market capitalization of $10.6 billion. Despite its progress, Vaxcyte faces a lengthy journey to approval, requiring three major clinical studies, manufacturing consistency work, and additional CMC activities.",
  "summary": null,
  "key_points": [
    "Company aims to submit Biologics License Application for VAX-31 in first half of 2028.",
    "Vaxcyte has $3.4 billion cash balance, $66.72 share price, and $10.6 billion market capitalization."
  ],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}